logo

Cerecor Inc. (CERC)



Trade CERC now with
  Date
  Headline
12/8/2020 7:18:11 AM Cerecor: FDA Accepts IND Application For CERC-007 For Treatment Of Relapsed Or Refractory Multiple Myeloma
12/1/2020 7:20:19 AM Cerecor Announces FDA Acceptance Of IND Application For CERC-803 To Treat Leukocyte Adhesion Deficiency Type II
11/17/2020 7:12:24 AM Cerecor To Partner With Frontiers CDG Consortium On Pivotal Trial Of CERC-801 For PGM1-CDG Treatment
8/26/2020 7:04:32 AM Cerecor Resumes Phase 1b Clinical Study Of CERC-002 In Anti-TNF Refractory Adult Crohn's Patients
8/3/2020 7:18:57 AM Cerecor Gets Orphan Drug Designation For CERC-006 In Lymphatic Malformations
7/21/2020 7:09:53 AM Cerecor Says First Patient Enrolled In Multicenter Proof-of-Concept Study Evaluating CERC-002 For COVID-19 ARDS
5/28/2020 7:08:05 AM Cerecor Receives FDA Clearance Of IND For CERC-002 In COVID-19 Induced ARDS
10/14/2019 6:35:13 AM Cerecor Agrees To Sell Pediatric Portfolio To AYTU BioScience In A Deal Valued In Excess Of $32 Mln
8/21/2019 6:37:59 AM Cerecor Receives Fast Track Designation From FDA For CERC-802 For Mannose-Phosphate Isomerase Deficiency
7/15/2019 6:35:53 AM Cerecor Enrolls First Patient Into CDG FIRST Trial
7/1/2019 6:35:51 AM Cerecor Announces Positive Final Results Of CERC-301 In The Treatment Of Neurogenic Orthostatic Hypotension
6/28/2019 6:49:24 AM Cerecor Says Added To Russell 3000 Index
2/19/2019 8:29:05 AM Cerecor Receives Fast Track Designation From FDA For CERC-801 For PGM1 Deficiency
2/15/2019 6:37:47 AM Cerecor Announces CERC-301 Granted U.S. Patent
1/28/2019 6:34:15 AM Cerecor Announces U.S. Headquarters Move Into Pharmaceutical Corridor Of Rockville, Maryland
1/22/2019 6:32:57 AM FDA Accepts IND Application For Cerecor’s Investigational Drug CERC-801 For PGM1 Deficiency